FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
The FDA has approved zidesamtinib for adults with ROS1-positive NSCLC after prior TKI treatment.
Asset / Drug
Drug and asset intelligence for zidesamtinib with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.